Literature DB >> 19223624

Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine.

Min Zhu1, Sanjeev Kaul, Partha Nandy, Dennis M Grasela, Marc Pfister.   

Abstract

Characterization of the time course and magnitude of enzyme induction due to multiple inducers is important for interpretation of clinical data from drug-drug interaction studies. A population interaction model was developed to quantify efavirenz autoinduction and further induction with concurrent carbamazepine coadministration. Efavirenz concentration data in the absence and presence of carbamazepine following single- and multiple-dose oral administrations in healthy subjects were used for model development. The proposed model was able to describe the time-dependent efavirenz autoinduction and the further induction with carbamazepine when the agents were combined. The estimated population averages of efavirenz oral clearance were 5.5, 9.4, 14.4, and 16.7 liters/h on days 1, 14, and 35 and at steady state for the interaction, respectively, for efavirenz monotherapy for 2 weeks followed by the coadministration of carbamazepine for 3 weeks. The estimated times to 50% of the steady state for efavirenz autoinduction and for the induction resulting from the concurrent administration of efavirenz and carbamazepine were similar (around 10 to 12 days). With this model-based analysis, efavirenz exposures can be projected prior to and at the steady state of induction, allowing a better understanding of the time course and magnitude of enzyme induction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223624      PMCID: PMC2687212          DOI: 10.1128/AAC.01120-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.

Authors:  Kathrin Klein; Thomas Lang; Tanja Saussele; Eduardo Barbosa-Sicard; Wolf-Hagen Schunck; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Pharmacogenet Genomics       Date:  2005-12       Impact factor: 2.089

2.  Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

Authors:  David Burger; Ilse van der Heiden; Charles la Porte; Marchina van der Ende; Paul Groeneveld; Clemens Richter; Peter Koopmans; Frank Kroon; Herman Sprenger; Jan Lindemans; Paul Schenk; Ron van Schaik
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  Further characterization of the expression in liver and catalytic activity of CYP2B6.

Authors:  S Ekins; M Vandenbranden; B J Ring; J S Gillespie; T J Yang; H V Gelboin; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

4.  Dose-dependent metabolism of carbamazepine in humans.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Epilepsy Res       Date:  1996-07       Impact factor: 3.045

5.  Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects.

Authors:  B Pascual-Sedano; A Iranzo; J Marti-Fàbregas; P Domingo; A Escartin; M Fuster; J L Barrio; M A Sambeat
Journal:  Arch Neurol       Date:  1999-05

6.  Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital.

Authors:  Niresh Hariparsad; Srikanth C Nallani; Rucha S Sane; Donna J Buckley; Arthur R Buckley; Pankaj B Desai
Journal:  J Clin Pharmacol       Date:  2004-11       Impact factor: 3.126

7.  Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

Authors:  Stephanie R Faucette; Hongbing Wang; Geraldine A Hamilton; Summer L Jolley; Darryl Gilbert; Celeste Lindley; Bingfang Yan; Masahiko Negishi; Edward L LeCluyse
Journal:  Drug Metab Dispos       Date:  2004-03       Impact factor: 3.922

Review 8.  Efavirenz.

Authors:  J C Adkins; S Noble
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 9.  Central nervous system disorders in AIDS.

Authors:  R M Levy; D E Bredesen; M L Rosenblum; R L Davis
Journal:  Immunol Ser       Date:  1989

Review 10.  Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.

Authors:  Jeffrey S Barrett; Line Labbé; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

View more
  25 in total

1.  Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.

Authors:  V Michaud; E Ogburn; N Thong; A O Aregbe; T C Quigg; D A Flockhart; Z Desta
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

2.  PharmGKB summary: carbamazepine pathway.

Authors:  Caroline F Thorn; Susan G Leckband; John Kelsoe; J Steven Leeder; Daniel J Müller; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

3.  Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.

Authors:  Gaik H Soon; Ping Shen; Eu-Leong Yong; Paul Pham; Charles Flexner; Lawrence Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

4.  Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection.

Authors:  William R Truong; Jason J Schafer; William R Short
Journal:  P T       Date:  2015-01

5.  Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.

Authors:  E D Kharasch; D Whittington; D Ensign; C Hoffer; P S Bedynek; S Campbell; K Stubbert; A Crafford; A London; T Kim
Journal:  Clin Pharmacol Ther       Date:  2012-03-07       Impact factor: 6.875

Review 6.  Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.

Authors:  Panjasaram Naidoo; Vasudevan V Chetty; Manoranjenni Chetty
Journal:  Eur J Clin Pharmacol       Date:  2014-01-05       Impact factor: 2.953

7.  Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.

Authors:  Kelly E Dooley; Jeong-Gun Park; Susan Swindells; Reena Allen; David W Haas; Yoninah Cramer; Francesca Aweeka; Ilene Wiggins; Amita Gupta; Patricia Lizak; Sonia Qasba; Rolf van Heeswijk; Charles Flexner
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

8.  Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers.

Authors:  Fan Zhang; Yan Li; Jingqiu Hu; Jinhua Zhong; Huafang Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

9.  In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.

Authors:  Cong Xu; Zeruesenay Desta
Journal:  Drug Metab Pharmacokinet       Date:  2013-02-05       Impact factor: 3.614

10.  Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.

Authors:  Julie B Dumond; Melanie R Nicol; Racheal N Kendrick; Samira M Garonzik; Kristine B Patterson; Myron S Cohen; Alan Forrest; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.